Extended-release paliperidone: Efficacy, safety and tolerability profile of a new atypical antipsychotic

Drugs of Today

Volumn 43, Issue 4, 2007, Pages 249-258

  Owen, Richard T ^a  

^a Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE; TRIMETHOPRIM; 9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AGITATION; AKATHISIA; AMENORRHEA; ANORGASMIA; ANXIETY; AREA UNDER THE CURVE; BODY MASS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GYNECOMASTIA; HEADACHE; HUMAN; IMPOTENCE; INSOMNIA; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SINUS TACHYCARDIA; SOMNOLENCE; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; DELAYED RELEASE FORMULATION; DRUG INTERACTION; HALF LIFE TIME;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HALF-LIFE; HUMANS; ISOXAZOLES; PYRIMIDINES; SCHIZOPHRENIA;

EID: 34447307434     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.4.1067342     Document Type: Review

References (28)

1. FDA approves risperdal for treatment of irritability associated with autistic disorder. Available at: http://www.medicalnewstoday.com/ medicalnews.php?newsid=53709. Accessed January 8, 2007.
2. Cardoni, A.A. Risperidone: Review and assessment of its role in the treatment of schizophrenia. Ann Pharmacother 1995, 29: 610-18.
3. Conley, R., Gupta, S.K., Sathyan, G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS®), an advanced oral delivery system. Curr Med Res Opin 2006, 22: 1879-92.
4. Invega™ (paliperidone) U.S. prescribing information, available at: http://www.invega.com. Accessed January 8, 2007.
5. Karlsson, P., Dencker, S., Nyberg, S. et al Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label single-dose studies. Clin Pharmacol Ther 2006, 79: 74, Abst. PIII-57.
6. Kapur, S., Seeman, P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001, 158: 360-9.
7. Cleton, A., Rossenu, S., Vermeulen, A. et al. A pharmacokinetic model to document the interconversion between paliperidone's enantiomers. Clin Pharmacol Ther 2006, 79: 55, Abst. PII-72.
8. Vermeir, M., Boom, S., Naessens, I., Talluri, K., Eerdekens, M. Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone in five healthy male subjects. Clin Pharmacol Ther 2006, 79: 80, Abst. PIII-78 and presented at Ann Meet Am Soc Clin Pharmacol Ther, Baltimore 2006, Poster PIII-78.
9. Thyssen, A., Crauwels, H., Cleton, A. et al Effects of hepatic impairment on the pharmacokinetics of immediate-release paliperidone. 46th Ann Meet New Clinical Drug Evaluation Unit, Boca Raton 2006, Session 1-90, Abst. 186.
10. Cleton, A., Cleton, K., Talluri, J. et al No pharmacokinetic interaction between trimethoprim and paliperidone ER in healthy subjects. Clin Pharmacol Ther 2006, 79: 22, Abst. PI-58.
11. Morosini, P.L., Magliano, L., Brambilla, L., Ugolini, S., Pioli, R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000, 101: 323-9.
12. Davidson, M., Emsley, R., Kramer, M. et al Efficacy, safety and effect on functioning of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: An international 6-week placebo-controlled study. Schiz Res 2006, 81 (Suppl. 1): Abst. 17.
13. Kane, J.M., Canas, F., Kramer, M. et al. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schiz Res 2007, 90: 147-61.
14. Marder, S.R., Kramer, M., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M. Efficacy and tolerability of two fixed dosages of paliperidone extended-release tablets in the treatment of acute schizophrenia: A 6-week placebo-controlled study. Neuropsychopharmacol 2005, 30 (Suppl. 1): Abst. 144.
15. Meltzer, H., Kramer, M., Gassmann-Mayer, C., Lim, P., Bobo, W., Eerdekens, M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 6-week placebo-controlled studies. Int J Neuropsychopharmacol 2006, 9 (Suppl. 1): S225-6 and presented at Collegium Internationale Neuropsychopharmacologicum, Chicago 2006, Poster P02.226.
16. Kramer, M., Nuamah, I., Lim, P., Canuso, C., Eerdekens, M. Onset of action of oral paliperidone extended-release tablets in patients with acute schizophrenia: Pooled results from three 6-week controlled studies. Int J Neuropsychopharmacol 2006, 9 (Suppl.1): S155 and presented at Collegium Internationale Neuropsychopharmacologicum, Chicago 2006, Poster P01.201.
17. Patrick, D.L., Adrianssen, I., Morosini, P., Rothman, M. Reliability, validity and sensitivity to change of the Personal and Social Performance scale in patients with acute schizophrenia. Int J Neuropsychopharmacol 2006, 9 (Suppl. 1): S287-8 and presented at Collegium Internationale Neuropsychopharmacologicum, Chicago 2006, Poster P03.225.
18. Dirks, B., Turkoz, I., Canuso, C., Youssef, E., Sliva, J.K., Gharabawi, G. Direct effect of paliperidone extended-release tablets on negative symptoms. 159th Ann Meet Am Psychiatr Assn, Toronto 2006, Abst. NR342.
19. Tzimos, A., Kramer, M., Ford, L., Gassmann-Mayer, C., Lim, P., Eerdekens, M. A 6-week placebo-controlled study on the safety and tolerability of flexibly dosed paliperidone extended-release tablets in the treatment of schizophrenia in elderly subjects. 159th Ann Meet Am Psychiatr Assn, Toronto 2006, Abst. NR441.
20. Emsley, R., Kramer, M., Nuamah, I., Lane, R., Lim, P., Mayarga, A., Eerdekens, M. Analysis of the efficacy and effect on function of paliperidone extended-release tablets in the treatment of young adults with schizophrenia. 159th Ann Meet Am Psychiatr Assn, Toronto 2006, Abst. NR345.
21. Kramer, M., Simpson, G., Maciulis, V. et al. Paliperidone extended-release tablets for the prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007, 27: 15-21.
22. Kostic, D., Bossie, C., Turkoz, I., Bouhours, P., Canuso, C. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. Int J Neuropsychopharmacol 2006, 9 (Suppl. 1): S161 and presented at Collegium Internationale Neuropsychopharmacologicum, Chicago 2006, Poster P01.224.
23. Marder, S., Kramer, M., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M. Paliperidone ex tended-release tablets in the treatment of schizophrenia. 46th Ann Meet New Clinical Drug Evaluation Unit, Boca Raton 2006, Session 1-75, Abst. 171.
24. Luthringer, R., Noel, N., Muzet, M. et al Paliperidone extended-release tablets: Effects on sleep in schizophrenia. Institute on Psychiatric Services, New York 2006, Poster 73.
25. Clay, A., Dreifus, L.S., Zaim, S., Kutalek, S.P. Can dispersion of the QT interval identify inducible mononorphic versus polymorphic ventricular tachycardia? Ann Noninvasive Electrocardiology 1998, 3: 20-4.
26. Meyer, J., Kramer, M., Kostic, D., Lane, R., Lim, P., Eerdekens, M. Metabolic outcomes in patients with schizophrenia treated with paliperidone extended-release tablets: Pooled analysis of three 6-week placebo-controlled studies. Int J Neuropsychopharmacol 2006, 9 (Suppl. 1): S282 presented at Collegium Internationale Neuropsychopharmacologicum, Chicago 2006, Poster P03.204.
27. Knegtering, R., Baselmans, P., Castelein, S., Bosker, F., Bruggerman, R., van den Bosch, R.J. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005, 162:1010-2.
28. Melkersson, K.I. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Human Psychopharmacol Clin Exp 2006, 21: 529-32.